Compare Natera Inc. Common Stock (NTRA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs PulteGroup, Inc. — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while PulteGroup, Inc. trades at $110.09 (market cap $21.25B). The key difference: Natera Inc. Common Stock is far larger — about 2.7× PulteGroup, Inc.'s market cap, and PulteGroup, Inc. pays a 0.93% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and PulteGroup, Inc. for 91 Days on average.
| NTRA | PHM | |
|---|---|---|
Market Cap | $57.03B | $21.25B |
Volume | 1,131,157 | 1,784,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $142.56 |
52-Week Low | $179.42 | $109.35 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $56.18B | $21.67B |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PulteGroup (PHM) trades at $111.58, down 0.4% with a bearish technical signal. The stock shows mixed earnings performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing. Revenue declined to $17.31B in 2025 with net income margin at 11.62%. Recent news highlights pressure from rising mortgage rates affecting homebuilder stocks, with PHM falling more than broader markets in September 2026.
The outlook remains cautious amid housing market headwinds from rising yields. Analyst consensus is divided with 45% buy ratings but a $139.64 price target suggests 25% upside. Key risks include mortgage rate sensitivity and competitive pressures, while valuation metrics appear reasonable with P/E of 11.4.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
